Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance
Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy. Mutations in the kinase domain of <i>BCR::ABL1</i> are the most extensively studied mechanism of TKI resistance...
Main Authors: | Ryo Yoshimaru, Yosuke Minami |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/18/13806 |
Similar Items
-
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
by: Massimo Breccia, et al.
Published: (2023-08-01) -
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
by: Hijiya N, et al.
Published: (2023-08-01) -
Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report
by: Awni Alshurafa, et al.
Published: (2024-01-01) -
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
by: Lucía Pérez-Lamas, et al.
Published: (2023-02-01) -
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
by: Sarah Tomassetti, et al.
Published: (2022-11-01)